Link and passcode for Teams meeting sent separately.

Agenda:

1. Update on potential LD-VenEx amendment trial comparing poDEC/LD-VenEx vs. AZA/LD-VenEx (5 min + 10 min discussion).
2. NAMLG – platform trial structure concept (5 min): Infrastructure with standing collaboration contracts (clinical trial agreement – CTA) and data processing agreements (DPAs) applicable for all types of trials. This would allow to open trials at one Nordic sponsor site and recruit pts from all Nordic Sites without the requirement to establish new CTAs / DPAs for each trial with individually. Ultimately, this will establish the NAMLG as partner for pharma-sponsored trials as well as to obtain funding for IIT.
3. List/overview of ongoing, already planned, and potential future AML trials in the Nordics.
4. Presentation and discussion of ongoing and potential novel AML trials
   1. Martin Jädersten – Salvage Treatment + HU (5 min + 5 min discission
   2. Oxcia: Presentation of MAATEO Karonudib + Dauno for RR AML (7 min+ 3 min discussion)
   3. Trials suggested in previous mail by Bjørn Tore Gjertsen (6 min + 4 min discussion)